Cardio Diagnostics has received a second extension from Nasdaq until June 2, 2025, to regain compliance with the minimum bid price requirement of $1.00 per share. This follows the company's initial 180-day compliance period that began on June 3, 2024, which expired without achieving compliance.The extension was granted based on the company meeting all Nasdaq Capital Market initial listing requirements except the minimum bid price requirement. To maintain listing, Cardio Diagnostics must achieve a closing bid price of at least $1.00 for a minimum of 10 consecutive business days before the new deadline. The company is considering various options, including a potential reverse stock split.If compliance is not achieved by June 2, 2025, the company faces potential delisting, though it would have the right to appeal before the Nasdaq Hearings Panel. Currently, this notice has no immediate impact on the trading status of the company's common stock.

Cardio Diagnostics has received a second extension from Nasdaq until June 2, 2025, to regain compliance with the minimum bid price requirement of $1.00 per share. This follows the company's initial 180-day compliance period that began on June 3, 2024, which expired without achieving compliance.The extension was granted based on the company meeting all Nasdaq Capital Market initial listing requirements except the minimum bid price requirement. To maintain listing, Cardio Diagnostics must achieve a closing bid price of at least $1.00 for a minimum of 10 consecutive business days before the new deadline. The company is considering various options, including a potential reverse stock split.If compliance is not achieved by June 2, 2025, the company faces potential delisting, though it would have the right to appeal before the Nasdaq Hearings Panel. Currently, this notice has no immediate impact on the trading status of the company's common stock.